ELN28
Hidradenitis Suppurativa (HS)
Pre-clinicalActive
Key Facts
About Elasmogen
Elasmogen is a clinical-stage biotech pioneering a novel class of biologics called soloMERs, which are single-domain, antibody-like proteins engineered for targeted drug delivery. Its lead candidate, ELN28, is a first-in-class, dual-acting conjugate targeting TNFα and JAK pathways for the treatment of Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition with significant unmet need. The company leverages an 'ADC-inspired' approach to achieve precision immunosuppression, aiming to improve efficacy and safety over existing biologics. Backed by UK and Scottish investors, Elasmogen is positioned to advance its innovative pipeline in immune-mediated diseases.
View full company profileTherapeutic Areas
Other Hidradenitis Suppurativa (HS) Drugs
| Drug | Company | Phase |
|---|---|---|
| Izokibep (Partnered) | Affibody | Phase 3 |
| Topical Roflumilast Foam 0.3% | Arcutis Biotherapeutics | Phase 2 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 |
| Tibulizumab (ZB-106) | Zura Bio | Phase 2 |